Clinical trial
An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer
NCT00529802 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer
- Lead sponsor
- University of Chicago
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- July 31, 2010
- Enrollment
- 60 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.